Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):

	Year ended December 31,
	2025		2024
Collaborative arrangement revenue	$	4,413	$	4,055
Less:
OCU400	9,871		$	6,846
OCU410 and OCU410ST	5,465		3,653
NeoCart	295		489
COVAXIN	(2)		25
Inhaled mucosal vaccine platform	417		2,464
OCU200	756		379
Unallocated costs:
Research and development personnel costs	16,786		12,992
Facilities and other support costs	3,581		2,984
Other (a)	2,581		2,294
Total research and development	39,750		32,126
General and administrative	27,579		26,686
Total operating expenses	67,329		58,812
Loss from operations	(62,916)		(54,757)
Other (expense) income:
Interest income	922		1,251
Interest expense	(5,188)		(688)
Other (expense) income, net	(664)		140
Total other (expense) income	(4,930)		703
Segment and consolidated net loss	$	(67,846)	$	(54,054)

(a) Other expenses include travel for research and development and a clinical and regulatory data repository system for each program.